Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration Drug approval summary

Clinical Cancer Research

Volumn 18, Issue 14, 2012, Pages 3722-3730

  Thornton, Katherine ^a   Kim, Geoffrey ^a   Maher, V Ellen ^a   Chattopadhyay, Somesh ^a   Tang, Shenghui ^a   Moon, Young Jin ^a   Song, Pengfei ^a   Marathe, Anshu ^a   Balakrishnan, Suchitra ^a   Zhu, Hao ^a   Garnett, Christine ^a   Liu, Qi ^a   Booth, Brian ^a   Gehrke, Brenda ^a   Dorsam, Robert ^a   Verbois, Leigh ^a   Ghosh, Debasis ^a   Wilson, Wendy ^a   Duan, John ^a   Sarker, Haripada ^a   Miksinski, Sarah Pope ^a   Skarupa, Lisa ^a   Ibrahim, Amna ^a   Justice, Robert ^a   Murgo, Anthony ^a   Pazdur, Richard ^a   more..

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; DOCETAXEL; PLACEBO; VANDETANIB;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ACNE; ADVANCED CANCER; ASPIRATION PNEUMONIA; ASTHENIA; BLURRED VISION; BRAIN ISCHEMIA; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CARDIOPULMONARY ARREST; CEREBROVASCULAR DISEASE; COLITIS; CONTROLLED STUDY; CORNEA OPACITY; COUGHING; DECREASED APPETITE; DEPRESSION; DERMATITIS; DIARRHEA; DISTRIBUTION VOLUME; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG APPROVAL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; DYSPHAGIA; ECZEMA; ERYTHRODERMA; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HAZARD RATIO; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOCALCEMIA; INOPERABLE CANCER; INSOMNIA; INTERSTITIAL LUNG DISEASE; ISCHEMIA; KERATOPATHY; LEUKOCYTE COUNT; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALIGNANT HYPERTENSION; MEDULLARY THYROID CANCER; METASTASIS POTENTIAL; NAUSEA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PANCREATITIS; PERITONITIS; PHOTOSENSITIVITY; PNEUMONIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY ARREST; RESPIRATORY FAILURE; REVIEW; RHINOPHARYNGITIS; SEPSIS; SIDE EFFECT; SKIN DISEASE; SMALL INTESTINE PERFORATION; STEVENS JOHNSON SYNDROME; SUDDEN DEATH; THROMBOCYTE COUNT; THYROID CANCER; TORSADE DES POINTES; TRANSIENT ISCHEMIC ATTACK; VOMITING; WEIGHT REDUCTION;

DISEASE-FREE SURVIVAL; DRUG APPROVAL; HUMANS; PIPERIDINES; QUINAZOLINES; THYROID NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84863890768     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0411     Document Type: Review

References (27)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996;276:1575-9.
3. Schilling T, B̈urck J, Sinn HP, Clemens A, Otto HF, Ḧoppner W, et al. Prognostic value of codon 918 (ATG!ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 2001;95:62-6.
4. Cirafici AM, Salvatore G, De Vita G, Carlomagno F, DathanNA, Visconti R, et al. Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential. Endocrinology 1997;138:1450-5. (Pubitemid 27137092)
5. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000;88:1139-48. (Pubitemid 30127676)
6. Austin LA, HeathH3rd. Calcitonin: physiology and pathophysiology.N Engl J Med 1981;304:269-78.
7. Barbet J, Campion L, Kraeber-Bodéré F, Chatal JF GTE Study Group. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005;90:6077-84. (Pubitemid 41606528)
8. Rosato L, Avenia N, Bernante P, De Palma M, Gulino G, Nasi PG, et al. Complications of thyroid surgery: analysis of a multicentric study on 14,934 patients operated on in Italy over 5 years. World J Surg 2004;28:271-6. (Pubitemid 38375527)
9. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006;107:2134-42. (Pubitemid 44665646)
10. Terezakis SA, Lee NY. The role of radiation therapy in the treatment of medullary thyroid cancer. J Natl Compr Canc Netw 2010;8:532-40, quiz 541.
11. Matuszczyk A, Petersenn S, Bockisch A, Gorges R, Sheu SY, Veit P, et al. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 2008;40:210-3. (Pubitemid 351690526)
12. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56:2155-60. (Pubitemid 16236586)
13. Gilliam LK, Kohn AD, Lalani T, Swanson PE, Vasko V, Patel A, et al. Capecitabine therapy for refractory metastatic thyroid carcinoma: a case series. Thyroid 2006;16:801-10. (Pubitemid 44757121)
14. Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany-Corone C, Schlumberger M. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC). Br J Cancer 2000;83:715-8.
15. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. American Thyroid Association Guidelines Task Force. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009;19:565-612.
16. Pacini F, Castagna MG, Cipri C, Schlumberger M. Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol) 2010;22:475-85.
17. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28:2323-30.
18. DeSouza JABN, Zimrin A. Phase II trial of sunitinib in medullary thyroid cancer (MTC). J Clin Oncol 2010;28:5504.
19. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009;27:3794-801.
20. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29:2660-6.
21. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010;95:2664-71.
22. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010; 28:767-72.
23. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30:134-41.
24. Pharmacology/toxicology NDA/BLA review and evaluation for vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer. 2010. [cited 2012 June 14]. Available at: http://www.accessdata.fda.gov/drugsatfda- docs/nda/2011/022405Orig1s000PharmR.pdf
25. Vandetanib (ZD6474) tablets Oncologic Drugs Advisory Committee (ODAC) meeting briefing document. 2010. [cited 2012 June 14]. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/OncologicDrugsAdvisoryCommittee/UCM235092.pdf
26. Clinical review for vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer. 2010. [cited 2012 June 14]. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/022405Orig1s000MedR.pdf
27. Brell JM. Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy. Prog Cardiovasc Dis 2010;53:164-72.